Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 4/20 | 0.87 |
| ▸ | FLT3 | P36888 | 2/20 | 0.87 |
| ▸ | MET | P08581 | 10/20 | 0.77 |
| ▸ | FLT1 | P17948 | 3/20 | 0.74 |
| ▸ | AXL | P30530 | 12/20 | 0.72 |
| ▸ | MERTK | Q12866 | 3/20 | 0.72 |
| ▸ | KDR | P35968 | 3/20 | 0.72 |
| ▸ | AURKA | O14965 | 1/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
| ▸ | PGR | P06401 | 1/20 | 0.72 |
| ▸ | LYN | P07948 | 1/20 | 0.72 |
| ▸ | RET | P07949 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | HCK | P08631 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16069957 | 0.96 | AURKB (0.87) | AURKBFLT3METFLT1AXL | |
| SCHEMBL372142 | 0.93 | AURKB (1.00) | AURKBFLT3METFLT1AXL | |
| SCHEMBL16083186 | 0.91 | MET (0.93) | AURKBFLT3METFLT1AXL | |
| SCHEMBL10244662 | 0.89 | AURKB (0.84) | AURKBFLT3METFLT1AXL | |
| SCHEMBL18676441 | 0.89 | AURKB (0.91) | AURKBFLT3METFLT1AXL | |
| SCHEMBL22521320 | 0.88 | MET (0.70) | AURKBFLT3METFLT1AXL | |
| SCHEMBL30918289 | 0.88 | AXL (0.90) | AURKBFLT3METFLT1AXL | |
| SCHEMBL15872120 | 0.88 | AXL (0.90) | AURKBFLT3METFLT1AXL | |
| SCHEMBL20952840 | 0.88 | AURKB (0.89) | AURKBFLT3METFLT1AXL | |
| SCHEMBL12026340 | 0.87 | AURKB (0.81) | AURKBFLT3METFLT1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002228-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200163954-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190218182-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-10273211-B2 | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20190076420-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2019-03-14 | — | — | US | disclosed |
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | EXELIXIS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2015142928-A1 | DOSING OF CABOZANTINIB FORMULATIONS | EXELIXIS, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| WO-2014145715-A1 | METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE | EXELIXIS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087143-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | AURKB 362/4885FLT3 39/4885MET 1/4885 |
| US-20190076420-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | AURKB 362/4885FLT3 39/4885MET 1/4885 |
| US-20210002228-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | NQO2, AURKA, CDC25B | AURKB 18/4885FLT3 434/4885MET 369/4885 |
| US-20200163954-A1 | Dosing of Cabozantinib Formulations | MET, ABL1, KRAS | AURKB 362/4885FLT3 39/4885MET 1/4885 |
| US-10273211-B2 | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | NQO2, AURKA, CDC25A | AURKB 20/4885FLT3 441/4885MET 380/4885 |
| US-20190218182-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | NQO2, AURKA, CDC25B | AURKB 18/4885FLT3 434/4885MET 369/4885 |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | IDH1, NTRK3, FGFR4 | AURKB 88/4885FLT3 451/4885MET 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.